
<DOC>
<DOCNO>WT03-B24-205</DOCNO>
<DOCOLDNO>IA064-000380-B023-224</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/library/tech/tech.htm 206.86.52.80 19970112101958 text/html 5547
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:20:03 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 5365
Last-modified: Thu, 05 Sep 1996 23:07:41 GMT
</DOCHDR>

<HTML>
<BODY background = "../../graphics/white-mi.gif">
<HEAD><TITLE>TECHNOLOGY</TITLE></HEAD>



<H1><CENTER>Technology</H1></CENTER>
<p>

<B><A HREF ="/BioCentury2/archive/1996/1qtr/031196b1.htm"> Emerging Company Profile: MitoKor </A></B><br>
This story describes technology developed by MitoKor to focus on diseases mediated by defects in mitochondrial DNA, especially in neurodegenerative and metabolic disorders. March 11, 1996 (1,210 words).<p>

<B><A HREF ="/BioCentury2/archive/1996/1qtr/030496b1.htm"> Emerging Company Profile: Inflammatics Inc.</A></B><br>
This story describes plans by Inflammatics to develop a cell-based immunotherapeutic vaccine for rheumatoid arthritis and other autoimmune reactions. March 4, 1996 (5,570 words).<p>

<B><A HREF ="/BioCentury2/archive/1996/1qtr/022696b1.htm"> Emerging Company Profile: Biotrin Holdings Ltd.</A></B><br>
This story describes Biotrin's biomarkers to detect demage and treatment effects in transplanted organs. Feb. 26, 1996 (1,500 words).<P>

<B><A HREF ="/BioCentury2/archive/1996/1qtr/010896b1.htm"> Emerging Company Profile: BioNumerik </A></B><BR>
This article describes BioNumerik Pharmaceuticals Inc.'s drug discovery program using supercomputers and molecular simulation software. Jan. 8, 1996 (1,150 words).<p>

<B><A HREF ="/BioCentury2/archive/1995/4qtr/121895b1.htm"> Emerging Company Profile: Jenner Technologies </A></B><BR>
This article describes Jenner Technologies Inc.'s technology for developing recombinant therapeutic vaccines for cancer. Dec. 18, 1995 (4,000 words).<p>


<B><A HREF ="/BioCentury2/archive/1995/4qtr/121195a4.htm"> U.S. NIH Report on Gene Therapy </A></B><BR>
This article summarizes a report to the Director of the National Institutes of Health. It concludes that the prospects for immediate clinical progress in gene therapy have been exaggerated. Dec. 11, 1995 (1000 words). The full report is posted on http://www.nih.gov/news<P>

<B><A HREF ="/BioCentury2/archive/1995/4qtr/1120a7.htm">Emerging Company Profile: Desmos</A></B><BR>
This article describes Desmos Inc.'s programs, which are focused on internal applications of tissue adhesion. The company is working on tissue engineering, cell therapy and organ transplantation. Nov. 20, 1995. (950 words)
<P>

<B><A HREF ="/BioCentury2/archive/1995/4qtr/1106c1.htm">Emerging Company Profile Exelixis</A></B><BR>

This article describes Exelixis Pharmaceuticals Inc.'s functional genomics program. The company uses living models to elucidate the connection between genes and disease in order to optimize drug targets. Nov. 6, 1995 (1,050 words).<p>


<B><A HREF ="../../archive/1995/4qtr/1023a8.htm">Emerging Company Profiles</A></B><BR>

BioCentury has begun a new weekly feature that profiles new biotechnology companies. This article on Apollon Inc. is one such profile. It describes Apollon's technology for facilitated DNA injections for vaccine or gene therapy. Oct. 23, 1995 (1,000 words).

<p>
<B><A HREF ="../../archive/1995/3qtr/0925a1.htm">Entrepreneural Europe</A></B><BR>

An increase in biotechnology ventures in Europe is causing discussion about 
whether entrepreneural enterprises are beginning to flower in Europe. This week 
on BioGlobe, BioCentury offers profiles of three such early stage companies, 
which are developing chimeric technology, gene therapy and "combinatorial 
biology." Sept. 25, 1995 (1,050 words)
<p>


<B><A HREF="../../archive/1995/3qtr/0731a1.htm">Sorting Out Fat From Fiction</A></B><BR>
This story addresses the publicity created by Amgen's OB mice and the dramatic increase in Amgen's market capitalization, and discusses what remains unknown about the human applications. (2,480 WORDS) In a related story, <A HREF="../../archive/1995/3qtr/0731a3.htm">Clinical Results</A>, three articles from <I>Science</I> authored by AMGN, Roche, and Rockefeller University are summarized. (2,400 WORDS) 31.7.31 <P>


<B><A HREF="../../archive/1995/2qtr/0612b1.htm">Questions About Amgen's Lead in TPO Race</A></B><BR>
In this story, Robertson, Stephens analyst Edward Hurwitz says Amgen's lead in thrombopoietin may be tenuous. He speculates that AMGN is developing a truncated version of TPO in order to be first to market. 12.6.95 (790 WORDS)<P>


<B><A HREF="../../archive/1995/1qtr/0221a1.htm">ALS Setback Raises Some Root Issues</A></B><BR>
This story discusses the implications of the demise of the Syntex/Synergen program in amyotrophic lateral sclerosis. It notes development of drugs to treat ALS has been slowed by lack of understanding of the disease and the absence of animal models. 21.2.95 (1,400 WORDS)<P>


<h5><HR>

<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0
<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/kanjipg.htm"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>

<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks of BioCentury Publications Inc. All other trade marks are the property of their respective owners. </H5><P>



</BODY></HTML>






</DOC>